Ellen Knutsen Rydberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ellen Knutsen Rydberg has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Olov Wiklund
From the Wallenberg Laboratory for Cardiovascular Research (E.K.R., A.K., C.U., K.E., O.W., B.G.O., L.M.H.); the Research Center for Endocrinology & Metabolism (P.-A.S., L.M.S.C.), Sahlgrenska University Hospital, Göteborg, Sweden; and Molecular Pharmacology (A.-C.J.-R, W.M.) and DMPK, Bioanalytical Chemistry (G.I.H.) AstraZeneca R&D, Mölndal, Sweden
2 shared publicationsAlexandra Krettek
From the Wallenberg Laboratory for Cardiovascular Research (E.K.R., A.K., C.U., K.E., O.W., B.G.O., L.M.H.); the Research Center for Endocrinology & Metabolism (P.-A.S., L.M.S.C.), Sahlgrenska University Hospital, Göteborg, Sweden; and Molecular Pharmacology (A.-C.J.-R, W.M.) and DMPK, Bioanalytical Chemistry (G.I.H.) AstraZeneca R&D, Mölndal, Sweden
1 shared publicationAnn-Cathrine JönSson-Rylander
From the Wallenberg Laboratory for Cardiovascular Research (E.K.R., A.K., C.U., K.E., O.W., B.G.O., L.M.H.); the Research Center for Endocrinology & Metabolism (P.-A.S., L.M.S.C.), Sahlgrenska University Hospital, Göteborg, Sweden; and Molecular Pharmacology (A.-C.J.-R, W.M.) and DMPK, Bioanalytical Chemistry (G.I.H.) AstraZeneca R&D, Mölndal, Sweden
1 shared publicationBertil G Ohlsson
1 shared publicationBertil G. Ohlsson
From the Wallenberg Laboratory for Cardiovascular Research (E.K.R., A.K., C.U., K.E., O.W., B.G.O., L.M.H.); the Research Center for Endocrinology & Metabolism (P.-A.S., L.M.S.C.), Sahlgrenska University Hospital, Göteborg, Sweden; and Molecular Pharmacology (A.-C.J.-R, W.M.) and DMPK, Bioanalytical Chemistry (G.I.H.) AstraZeneca R&D, Mölndal, Sweden
1 shared publicationChristina Ullström
From the Wallenberg Laboratory for Cardiovascular Research (E.K.R., A.K., C.U., K.E., O.W., B.G.O., L.M.H.); the Research Center for Endocrinology & Metabolism (P.-A.S., L.M.S.C.), Sahlgrenska University Hospital, Göteborg, Sweden; and Molecular Pharmacology (A.-C.J.-R, W.M.) and DMPK, Bioanalytical Chemistry (G.I.H.) AstraZeneca R&D, Mölndal, Sweden
1 shared publication
Latest Publications
- 1 November 2004
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (11) , 2040-2045
Hypoxia Increases LDL Oxidation and Expression of 15-Lipoxygenase-2 in Human Macrophages
Objective— Macrophage-mediated oxidation of low-density lipoprotein (LDL) by enzymes, such as the lipoxygenases, is considered of major importance for the formation of oxidized LDL during atherogenesis. Macrophages have been identified in hypoxic areas in atherosclerotic plaques. Methods and Results— To investigate the role of hypoxia in macrophage-mediated LDL oxidation, we incubated human monocyte-derived macrophages with LDL under normoxic (21% O 2 ) or hypoxic (0% O 2 ) conditions. The results showed that hypoxic macrophages oxidized LDL to a significantly higher extent than normoxic cells. Interestingly, the mRNA and protein expression of 15-lipoxygenase-2 (15-LOX-2) as well as the activity of this enzyme are elevated in macrophages incubated at hypoxia. Both the unspliced 15-LOX-2 and the spliced variant 15-LOX-2sv-a are found in macrophages. In addition, 15-LOX-2 was identified in carotid plaques in some macrophage-rich areas but was only expressed at low levels in nondiseased arteries. Conclusions— In summary, these observations show for the first time that 15-LOX-2 is expressed in hypoxic macrophages and in atherosclerotic plaques and suggest that 15-LOX-2 may be one of the factors involved in macrophage-mediated LDL oxidation at hypoxia.
- 1 November 2004
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (11) , 2040-2045
Hypoxia Increases LDL Oxidation and Expression of 15-Lipoxygenase-2 in Human Macrophages
Objective— Macrophage-mediated oxidation of low-density lipoprotein (LDL) by enzymes, such as the lipoxygenases, is considered of major importance for the formation of oxidized LDL during atherogenesis. Macrophages have been identified in hypoxic areas in atherosclerotic plaques. Methods and Results— To investigate the role of hypoxia in macrophage-mediated LDL oxidation, we incubated human monocyte-derived macrophages with LDL under normoxic (21% O 2 ) or hypoxic (0% O 2 ) conditions. The results showed that hypoxic macrophages oxidized LDL to a significantly higher extent than normoxic cells. Interestingly, the mRNA and protein expression of 15-lipoxygenase-2 (15-LOX-2) as well as the activity of this enzyme are elevated in macrophages incubated at hypoxia. Both the unspliced 15-LOX-2 and the spliced variant 15-LOX-2sv-a are found in macrophages. In addition, 15-LOX-2 was identified in carotid plaques in some macrophage-rich areas but was only expressed at low levels in nondiseased arteries. Conclusions— In summary, these observations show for the first time that 15-LOX-2 is expressed in hypoxic macrophages and in atherosclerotic plaques and suggest that 15-LOX-2 may be one of the factors involved in macrophage-mediated LDL oxidation at hypoxia.
- 1 October 2003
- Published by Elsevier in Atherosclerosis
- Vol. 170 (2) , 245-252
Hypoxia increases 25-hydroxycholesterol-induced interleukin-8 protein secretion in human macrophages
- 1 October 2003
- Published by Elsevier in Atherosclerosis
- Vol. 170 (2) , 245-252
Hypoxia increases 25-hydroxycholesterol-induced interleukin-8 protein secretion in human macrophages